Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/02/2874217/0/en/Wave-Life-Sciences-First-Quarter-2024-Financial-Results-Scheduled-for-May-9-2024.html
https://www.globenewswire.com/news-release/2024/04/30/2872240/0/en/Wave-Life-Sciences-Announces-Approval-of-First-Clinical-Trial-Application-for-RestorAATion-2-Trial-of-WVE-006-in-Individuals-with-Alpha-1-Antitrypsin-Deficiency-AATD.html
https://www.globenewswire.com/news-release/2024/04/23/2867671/0/en/Wave-Life-Sciences-Announces-Continued-Momentum-in-GSK-Collaboration-and-Advancements-in-siRNA-and-RNA-Editing.html
https://www.globenewswire.com/news-release/2024/03/27/2853165/0/en/Wave-Life-Sciences-to-Present-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/03/06/2841296/0/en/Wave-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2024/02/28/2836961/0/en/Wave-Life-Sciences-Fourth-Quarter-and-Full-Year-2023-Financial-Results-Scheduled-for-March-6-2024.html
https://www.globenewswire.com//news-release/2024/02/27/2836039/0/en/Wave-Life-Sciences-Announces-Upcoming-Presentations-at-MDA-Conference-that-Highlight-Best-in-Class-Potential-for-WVE-N531-in-Duchenne-Muscular-Dystrophy.html
https://www.globenewswire.com//news-release/2024/01/08/2805412/0/en/Wave-Life-Sciences-Highlights-Recent-Achievements-and-Upcoming-2024-Milestones.html
https://www.globenewswire.com//news-release/2024/01/03/2803312/0/en/Wave-Life-Sciences-to-Present-at-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/12/15/2797042/0/en/Wave-Life-Sciences-Announces-Initiation-of-Dosing-in-Phase-2-FORWARD-53-Trial-of-WVE-N531-in-Duchenne-Muscular-Dystrophy.html